Galderma has received filing acceptances for nemolizumab for the treatment of prurigo nodularis and atopic dermatitis in Australia, Singapore, Switzerland and the United Kingdom, the company ...

Galderma has announced positive data from three phase 3 studies that evaluated nemolizumab for the treatment of atopic dermatitis and prurigo nodularis, according to a company press release ...

Primary support for the approval came from the OLYMPIA 1 and 2 trials, which involved a combined total of more than 500 patients with prurigo nodularis. In the two trials, 26% and 38% of patients ...

Nemolizumab is the first and only biologic approved for both prurigo nodularis and atopic dermatitis, with 4-week dosing intervals from the start of treatment. 1 Additionally, nemolizumab is the ...

The U.S. Food and Drug Administration and European Medicines Agency also accepted filing submissions for nemolizumab for the treatment of prurigo nodularis and atopic dermatitis in February 2024 ...

July 19, 2004 -- Thalidomide reduces the signs and symptoms of prurigo nodularis (PN) of human immunodeficiency virus (HIV), but one third of patients develop peripheral neuropathy, according to ...

About prurigo nodularis Prurigo nodularis is a chronic, debilitating, and distinct neuroimmune skin disease characterized by the presence of intense itch and thick skin nodules covering large body ...